DENTSPLY SIRONA Inc. (XRAY - Free Report) recently announced preliminary results for fourth-quarter 2018 wherein the top line surpassed the Zacks Consensus Estimate of $1.02 billion.
Revenues totaled at $1.06 billion, showing a fall of 2.9% year over year.
Adjusted earnings per share came in at 58 cents, beating the Zacks Consensus Estimate of 54 cents. Earnings declined 29.3% year over year.
Investors Cheerful
DENTSPLY’s preliminary fourth-quarter 2018 results seem to impress investors. Share price of this Zacks Rank #3 (Hold) stock rose 4.6% to close at $49.13 since the release.
In the past year, shares of DENTSPLY have declined 12.1%, comparing favorably with the industry's 1.3% fall. The current level is also lower than the S&P 500’s rally of 3.3%.
2018 Results
Revenues in 2018 are expected at $4 billion, surpassing the Zacks Consensus Estimate of $3.94 billion. Revenues fell 0.2% from 2017.
Earnings per share for 2018 were $2.01, beating the Zacks Consensus Estimate of $1.97. The figure dropped 24.4% from 2017.
Quarter Highlights
Revenues in the fourth quarter are expected to see solid year-over-year increase of 4.6% in Europe and 1.4% in rest of the world. However, U.S. revenues declined 14.7% on a year-over-year basis in the quarter.
Fourth-quarter Consumable revenues increased 3.4% year over year. Notably, the segment benefited from a recovery in shipment levels at the company’s European distribution center in Venlo, the Netherlands.
Technology & Equipment revenues declined 7.4% year over year.
2019 View
For 2019, DENTSPLY expects adjusted earnings per share within the range of $2.25-$2.40. The mid-point of $2.32 of the guided range lies above the Zacks Consensus Estimate of $2.15.
However, portfolio initiatives are expected to negatively impact 2019 revenues.
Key Picks
Some better-ranked stocks in the broader medical space are Abbott Laboratories (ABT - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Surmodics, Inc. (SRDX - Free Report) .
Abbott’s long-term earnings growth rate is projected at 11.7%. The stock has a Zacks Rank #2 (Buy).
Merit Medical’s long-term earnings growth rate is projected at 13%. The stock has a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is expected at 10%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
DENTSPLY SIRONA Inc. (XRAY - Free Report) recently announced preliminary results for fourth-quarter 2018 wherein the top line surpassed the Zacks Consensus Estimate of $1.02 billion.
Revenues totaled at $1.06 billion, showing a fall of 2.9% year over year.
Adjusted earnings per share came in at 58 cents, beating the Zacks Consensus Estimate of 54 cents. Earnings declined 29.3% year over year.
Investors Cheerful
DENTSPLY’s preliminary fourth-quarter 2018 results seem to impress investors. Share price of this Zacks Rank #3 (Hold) stock rose 4.6% to close at $49.13 since the release.
In the past year, shares of DENTSPLY have declined 12.1%, comparing favorably with the industry's 1.3% fall. The current level is also lower than the S&P 500’s rally of 3.3%.
2018 Results
Revenues in 2018 are expected at $4 billion, surpassing the Zacks Consensus Estimate of $3.94 billion. Revenues fell 0.2% from 2017.
Earnings per share for 2018 were $2.01, beating the Zacks Consensus Estimate of $1.97. The figure dropped 24.4% from 2017.
Quarter Highlights
Revenues in the fourth quarter are expected to see solid year-over-year increase of 4.6% in Europe and 1.4% in rest of the world. However, U.S. revenues declined 14.7% on a year-over-year basis in the quarter.
Fourth-quarter Consumable revenues increased 3.4% year over year. Notably, the segment benefited from a recovery in shipment levels at the company’s European distribution center in Venlo, the Netherlands.
Technology & Equipment revenues declined 7.4% year over year.
2019 View
For 2019, DENTSPLY expects adjusted earnings per share within the range of $2.25-$2.40. The mid-point of $2.32 of the guided range lies above the Zacks Consensus Estimate of $2.15.
However, portfolio initiatives are expected to negatively impact 2019 revenues.
Key Picks
Some better-ranked stocks in the broader medical space are Abbott Laboratories (ABT - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and Surmodics, Inc. (SRDX - Free Report) .
Abbott’s long-term earnings growth rate is projected at 11.7%. The stock has a Zacks Rank #2 (Buy).
Merit Medical’s long-term earnings growth rate is projected at 13%. The stock has a Zacks Rank #2.
Surmodics’ long-term earnings growth rate is expected at 10%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ABT - FREE
Get the latest research report on XRAY - FREE
Get the latest research report on SRDX - FREE
Get the latest research report on MMSI - FREE